Underwriting

Vitru Limited Announces Pricing of Initial Public Offering

Corporate finance, Financial economics, Initial public offering, Stock market, U.S. Securities and Exchange Commission, Financial markets, Prospectus, SEC filing, Registration statement, Security, Public offering, Underwriting

Friday, September 18, 2020 - 12:16pm

FLORIANPOLIS, Brazil, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Vitru Limited (Vitru), a Brazilian distance learning education group company, today announced the pricing of its initial public offering of 6,000,000 of its newly-issued common shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC) at a public offering price of $16.00 per share.

Key Points:

FLORIANPOLIS, Brazil, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Vitru Limited (Vitru), a Brazilian distance learning education group company, today announced the pricing of its initial public offering of 6,000,000 of its newly-issued common shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC) at a public offering price of $16.00 per share.
In connection with the offering, Vitru has granted the underwriters a 30-day option to purchase up to an additional 900,000 common shares at the initial public offering price, less underwriting discounts and commissions.
The offering will be made only by means of a prospectus.
A registration statement on Form F-1 relating to these securities has been filed with, and declared effective by, the SEC.

Athira Pharma Announces Pricing of Initial Public Offering

Finance, Financial markets, Financial economics, Corporate finance, Stock market, Athira Pharma, Initial public offering, Underwriting, Public offering, Stock, NASDAQ

Friday, September 18, 2020 - 1:21am

SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (Athira), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $17.00 per share.

Key Points:

SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (Athira), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $17.00 per share.
All of the shares of common stock are being offered by Athira.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira, are expected to be$204.0 million.
In addition, Athira has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of Athiras common stock at the initial public offering price less the underwriting discounts and commissions.

Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”

Infectious diseases, Biotechnology, Pharmaceutical, Health, Finance, Money, Financial markets, Initial public offering, Stock market, Corporate finance, Actuarial science, Underwriting, Public offering, Roth Capital Partners, Security, NASDAQ

Friday, September 18, 2020 - 1:30am

Humanigen also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the public offering price, less underwriting discounts and commissions.

Key Points:

Humanigen also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the public offering price, less underwriting discounts and commissions.
J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.
Bryan, Garnier & Co. is acting as the European lead manager and H.C. Wainwright & Co., National Securities Corporation and Roth Capital Partners are acting as co-managers for the offering.
As previously announced, Humanigens stock will commence trading on the Nasdaq Capital Market on Friday, September 18, 2020, under the symbol HGEN.

Unity Announces Pricing of Initial Public Offering

Friday, September 18, 2020 - 12:46am

Unity Software Inc. (Unity) today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a price to the public of $52.00 per share.

Key Points:

Unity Software Inc. (Unity) today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a price to the public of $52.00 per share.
In addition, Unity has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.
Goldman Sachs & Co. LLC and Credit Suisse Securities (USA) LLC are acting as lead book-running managers for the proposed offering.
Oppenheimer & Co., Piper Sandler, Stifel, Wedbush Securities, Academy Securities and Siebert Williams Shank are acting as co-managers for the offering.

Alpha Healthcare Acquisition Corp. Announces Pricing of $100,000,000 Initial Public Offering

Offering, Oppenheimer Holdings, Underwriting, Finance, Initial public offering, Companies, Corporate finance, Financial economics, Stock market

Thursday, September 17, 2020 - 10:48pm

New York, NY, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (the Company) announced today that it priced its initial public offering of 10,000,000 units at $10.00 per unit.

Key Points:

New York, NY, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (the Company) announced today that it priced its initial public offering of 10,000,000 units at $10.00 per unit.
Oppenheimer & Co. Inc. is acting as the sole book running manager for the offering and Northland Capital Markets is acting as co-manager for the offering.
The Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 units at the initial public offering price to cover over-allotments, if any.
This press release contains statements that constitute forward-looking statements, including with respect to the initial public offering.

Outset Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Thursday, September 17, 2020 - 9:01pm

Outset Medical, Inc. (Nasdaq: OM) (Outset) today announced the closing of its initial public offering of 10,293,777 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,342,666 additional shares of common stock, at the initial public offering price of $27.00 per share.

Key Points:

Outset Medical, Inc. (Nasdaq: OM) (Outset) today announced the closing of its initial public offering of 10,293,777 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,342,666 additional shares of common stock, at the initial public offering price of $27.00 per share.
The gross proceeds to Outset, before deducting underwriting discounts and commissions and offering expenses, were approximately $277.9 million.
The shares began trading on The Nasdaq Global Select Market on September 15, 2020, under the symbol "OM."
Outset Medical, Inc. is a rapidly growing medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis.

Chewy, Inc. Announces Pricing of Offering of Class A Common Stock

Retail, Online Retail, Pets, Consumer, Financial markets, Stock market, Financial economics, Finance, Corporate finance, Chewy, Stock, Option, Underwriting

Thursday, September 17, 2020 - 1:21pm

Chewy, Inc. (Chewy) (NYSE: CHWY) today announced that it has priced its underwritten public offering (the Offering) of 5.1 million shares of its Class A common stock at a price of $55.25 per share.

Key Points:

Chewy, Inc. (Chewy) (NYSE: CHWY) today announced that it has priced its underwritten public offering (the Offering) of 5.1 million shares of its Class A common stock at a price of $55.25 per share.
The Company has granted the underwriter an option to purchase up to 765,000 additional shares of Class A common stock.
The Company expects to use the net proceeds from the Offering for general corporate purposes, including growth initiatives to expand our total addressable market.
The Offering is expected to close on September 21, 2020, subject to customary closing conditions.

NuCana Announces Pricing of a Public Offering of American Depositary Shares

Initial public offering, Financial economics, Finance, Stock market, Money, Corporate finance, Financial markets, Prospectus, Registration statement, Underwriting, ADSS, Public offering

Thursday, September 17, 2020 - 12:00pm

In addition, NuCana has granted the underwriters a 30-day option to purchase up to 2,333,333 additional ADSs at the public offering price, less underwriting discounts and commissions.

Key Points:

In addition, NuCana has granted the underwriters a 30-day option to purchase up to 2,333,333 additional ADSs at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about September 21, 2020, subject to the satisfaction of customary closing conditions.
Jefferies, Cowen, William Blair, and Truist Securities are acting as joint book-running managers for the offering.
This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.

Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares

Actuarial science, Underwriting, Initial public offering, Stock market, Finance

Thursday, September 17, 2020 - 4:29am

The Company is offering 11,111,111 ordinary shares at a price to the public of $2.25 per share for total gross proceeds of approximately $25.0 million, before deducting the underwriting discount and estimated offering expenses payable by the Company.

Key Points:

The Company is offering 11,111,111 ordinary shares at a price to the public of $2.25 per share for total gross proceeds of approximately $25.0 million, before deducting the underwriting discount and estimated offering expenses payable by the Company.
The offering is expected to close on or about September 21, 2020, subject to the satisfaction of customary closing conditions.
In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 1,666,666 ordinary shares on the same terms and conditions.
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Sumo Logic Announces Pricing of Initial Public Offering

Initial public offering, Financial economics, Information technology, Finance, Corporate finance, Information technology management, Network management, Sumo Logic, System administration, Underwriting, Sumo, Public offering

Thursday, September 17, 2020 - 3:31am

REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Sumo Logic, Inc. (Sumo Logic) today announced the pricing of its initial public offering of 14,800,000 shares of its common stock at a price of $22.00 per share.

Key Points:

REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Sumo Logic, Inc. (Sumo Logic) today announced the pricing of its initial public offering of 14,800,000 shares of its common stock at a price of $22.00 per share.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sumo Logic, are expected to be $325.6 million.
In addition, Sumo Logic has granted the underwriters a 30-day option to purchase up to an additional 2,220,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Sumo Logic delivers its platform as a true, multi-tenant SaaS architecture, across multiple use-cases, enabling businesses to thrive in the Intelligence Economy.